Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Technosphere Inhalation Powder (FDKP), Technosphere, Technosphere Inhalation Powder, Technosphere Powder
Technosphere/Insulin · 3 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| T Inhalation powder in diabetic subjs w/ normal renal func | EXPERIMENTAL | T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units |
| T Inhalation powder diabetic subj w/mild or moderate nephrop | EXPERIMENTAL | T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units |
| Non-Diabetic Subj. w/o COPD | EXPERIMENTAL | Single dose, 30 units |
| Non-Diabetic Subj. with COPD | EXPERIMENTAL | Single dose, 30 units |
| Name | Type | Description |
|---|---|---|
| Technosphere/Insulin | DRUG | - |
| Technosphere Inhalation Powder | DRUG | Technosphere Inhalation Powder |
| Technosphere®/Insulin | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of type 2 diabetes mellitus. * Current regimen of intensified insulin therapy for at least 6 months. * Body Mass Index less than 35 kg/m2. * HbA1c less than or equal to 9%. * Non-smoker for at least 2 years. * If medications in addition to insulin are taken ...
Technosphere/Insulin is an inhaled dry powder insulin formulation developed by MannKind Corporation. It is delivered as Technosphere Inhalation Powder and has been studied in clinical trials for type 2 diabetes mellitus, chronic obstructive pulmonary disease (COPD), and mild nephropathy. It remains an investigational product in clinical development.
Technosphere/Insulin has been studied for type 2 diabetes mellitus, chronic obstructive pulmonary disease (COPD), and mild nephropathy. Trials have evaluated insulin absorption after inhalation in non-diabetic patients with and without COPD, and compared inhaled insulin with subcutaneously injected insulin in type 2 diabetes.
Technosphere/Insulin is developed by MannKind Corporation, which trades under the ticker MNKD. MannKind is the sponsor of the clinical trials evaluating the Technosphere Inhalation Powder formulation across diabetes and respiratory conditions.
Technosphere/Insulin is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. Completed studies include Phase 1 trials in COPD and mild nephropathy, along with a Phase 2 trial in type 2 diabetes mellitus.
Technosphere/Insulin has been evaluated in completed trials including NCT01021891, a Phase 1 study of insulin blood levels after inhalation in non-diabetic patients with and without COPD, and NCT00626249, a Phase 1 study in diabetic subjects with mild or moderate kidney disease. A Phase 2 trial, NCT00419302, compared inhaled with injected insulin in type 2 diabetes.
Yes. Technosphere/Insulin is also known as Technosphere Inhalation Powder, Technosphere Inhalation Powder (FDKP), Technosphere, and Technosphere Powder. These names refer to the same inhaled dry powder insulin formulation developed by MannKind Corporation.